Imaging Follow-up After Stone Treatment
Imaging Follow-up of Patients With Urinary Stones: Ultrasound-Based Randomized Controlled Trial
Kidney stones are a common condition that can recur even after successful treatment. Regular imaging tests can help detect new stones, but frequent use of X-rays and CT scans can expose patients to unnecessary radiation. It is not yet clear how often patients should have imaging tests after treatment.
This study compares two schedules for monitoring patients who have undergone treatment for kidney stones and have no significant remaining stones. Participants are randomly assigned to one of two groups. One group has an ultrasound examination of the kidneys and urinary tract every 6 months, while the other group has the same examination every 12 months.
The study aims to determine whether more frequent ultrasound examinations can reduce unexpected episodes related to kidney stones, such as pain, bleeding in the urine, or urinary infections caused by blocked urine flow.
The researchers will also assess changes in kidney function, visits to the emergency department, the number of imaging tests performed, the development or growth of stones without symptoms, and the overall cost of imaging.
The study includes adults with a low or high risk of kidney stones recurrence and is conducted at Sismanoglio General Hospital in Athens, Greece.
The findings may help determine an appropriate schedule for monitoring patients after kidney stone treatment while reducing unnecessary tests, radiation exposure, and healthcare costs.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lazaros Tzelves
- Phone Number: 00306944104974
- Email: lazarostzelves@gmail.com
Study Contact Backup
- Name: Panagiotis Neofytou
- Phone Number: 00306996288898
- Email: neo.panagiotis@gmail.com
Study Locations
-
-
Attica
-
Athens, Attica, Greece, 15126
- 2nd Department of Urology, Sismanoglio General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 years or older, including both males and females.
- Patients with urolithiasis of any stone composition.
- Patients with stones at any anatomical location.
- Patients undergoing any definitive stone treatment procedure, including extracorporeal shock wave lithotripsy (SWL), ureteroscopy (URS), retrograde intrarenal surgery (RIRS), or percutaneous nephrolithotomy (PCNL).
- Patients classified as either low-risk or high-risk for stone recurrence according to European Association of Urology (EAU) criteria.
- Patients with no significant residual stone fragments following treatment, defined as the absence of residual fragments larger than 2 mm at 4-6 weeks after the procedure, assessed by radiography and ultrasound or low-dose computed tomography.
Exclusion Criteria:
- Refusal to participate in the study.
- Patients with anatomical abnormalities or a history of previous open surgery for stone disease.
- Patients with a solitary kidney or chronic kidney disease.
- Patients with occupations considered to be associated with a high risk of stone disease, such as pilots.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 6-monthly ultrasound follow-up
|
kidney, ureter, bladder ultrasound every 6 months kidney, ureter, bladder ultrasound every 12 months |
|
Active Comparator: 12-monthly ultrasound follow-up
|
kidney, ureter, bladder ultrasound every 6 months kidney, ureter, bladder ultrasound every 12 months |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Symptomatic Stone Episodes
Time Frame: from randomization until the end of follow-up period, 1 year after intervention
|
Occurrence of symptomatic stone episodes during a one-year follow-up period, defined as any of the following: a new episode of renal colic or pain, hematuria not attributable to another cause, or urinary tract infection associated with obstruction caused by a newly formed stone. In patients with no visible residual stone fragments after treatment, the detection of any stone during follow-up will be considered recurrence. In patients with residual fragments smaller than 2 mm, detection of any fragment measuring 3 mm or larger will be considered recurrence. |
from randomization until the end of follow-up period, 1 year after intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Time Frame: from randomization until the end of follow-up period, 1 year after intervention
|
Change in estimated glomerular filtration rate (eGFR) during the follow-up period, as an indicator of changes in kidney function. |
from randomization until the end of follow-up period, 1 year after intervention
|
|
Number of Emergency Department Visits
Time Frame: from randomization until the end of follow-up period, 1 year after intervention
|
Number of visits to the emergency department during the follow-up period. |
from randomization until the end of follow-up period, 1 year after intervention
|
|
Number of Imaging Examinations Performed
Time Frame: from randomization until the end of follow-up period, 1 year after intervention
|
Total number of imaging examinations performed during the follow-up period for the evaluation of urolithiasis, including plain radiographs, computed tomography scans, and ultrasound examinations. |
from randomization until the end of follow-up period, 1 year after intervention
|
|
Incidence of Asymptomatic Stone Growth
Time Frame: from randomization until the end of follow-up period, 1 year after intervention
|
Number of patients who develop asymptomatic stone growth during the follow-up period, as detected by imaging examinations. |
from randomization until the end of follow-up period, 1 year after intervention
|
|
Total Cost of Imaging Examinations
Time Frame: from randomization until the end of follow-up period, 1 year after intervention
|
Total cost of imaging examinations performed during the follow-up period for the evaluation and monitoring of urolithiasis. |
from randomization until the end of follow-up period, 1 year after intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 5949/21.01.2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.